Tag

Long Acting Injectable

All articles tagged with #long acting injectable

Months-Long Shield Against Fentanyl: San Francisco's Breakthrough Addiction Therapy
health1 month ago

Months-Long Shield Against Fentanyl: San Francisco's Breakthrough Addiction Therapy

San Francisco is expanding long-acting injectable buprenorphine to treat fentanyl addiction, a therapy that blocks opioids for weeks and has shown higher retention than daily meds: the city logged about 1,400 injections in 2024 and 2,800 in 2025, with jail programs reporting 43% follow-up after release versus 29% for daily-pill users. While promising, the first dose can cause intense withdrawal if dosing is not precise, and some patients still relapse. Experts view this as a major breakthrough that could widen access beyond SF as research continues.

Weekly Long-Acting Injection Offers New Hope for Parkinson’s Tremor Relief
health7 months ago

Weekly Long-Acting Injection Offers New Hope for Parkinson’s Tremor Relief

Scientists from the University of South Australia have developed a biodegradable, long-acting injectable gel that delivers levodopa and carbidopa steadily over a week, potentially transforming Parkinson's treatment by reducing dosing frequency and improving patient compliance. The formulation has shown promising safety and effectiveness in lab tests, with plans for clinical trials and commercialization.

FDA Approves Long-Lasting HIV Prevention Injection
health8 months ago

FDA Approves Long-Lasting HIV Prevention Injection

A new FDA-approved long-acting injectable drug called Yestugo offers up to six months of HIV protection, providing an alternative to daily pills but not preventing other STIs. Experts emphasize that it should complement, not replace, comprehensive sexual health practices like condom use, especially as STI rates, such as genital discharge syndromes, continue to rise in Jamaica. The medication is expected to improve adherence for those struggling with daily regimens, but awareness of its limitations remains crucial.

Maximizing HIV Prevention: Swift Implementation of Long-Acting Cabotegravir
health2 years ago

Maximizing HIV Prevention: Swift Implementation of Long-Acting Cabotegravir

The rollout of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV without delay can have a significant impact on the HIV epidemic, particularly in settings with high HIV incidence. A study showed that CAB-LA was superior to the daily oral regimen in preventing HIV infection. By expanding PrEP coverage with CAB-LA, the projected HIV incidence decreased in simulation models for Atlanta, Montreal, and the Netherlands. Increasing PrEP coverage by 11 percentage points by 2032 could lead to a reduction of over 45% in new HIV acquisitions. Offering CAB-LA to current and prospective PrEP patients could improve adherence and increase the effectiveness of HIV prevention.